<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788749</url>
  </required_header>
  <id_info>
    <org_study_id>GRAY07</org_study_id>
    <nct_id>NCT00788749</nct_id>
  </id_info>
  <brief_title>Medical Polypectomy and Predictors of Response</brief_title>
  <official_title>A Proof Of Concept Study to Investigate the Clinical, Histological And Molecular Predictors of Response to Oral and Intranasal Corticosteroid in Nasal Polyposis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chief Scientist Office of the Scottish Government</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Tayside</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first randomized parallel group clinical trial looking at oral prednisolone
      induced medical nasal polypectomy followed by maintenance on topical steroid therapy in
      patients with nasal polyposis. This study also looks at the effect of aspirin sensitivity and
      the factors linking nasal polyps with asthma. We have also taken baseline measurements of a
      variety of blood, surface and biopsy markers to assess for potential to predict steroid
      response. Finally, the still unchartered link between nasal polyps and asthma will be
      explored by measuring Staphylococcal superantigens in serum before and after treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endoscopy Polyp Grading</measure>
    <time_frame>0, 2 weeks, 10 weeks, 28 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mini RQLQ</measure>
    <time_frame>0, 2 wks, 10 wks, 28 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNS-4</measure>
    <time_frame>0, 2 wks, 10 wks, 28 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PNIF</measure>
    <time_frame>0,2 wks, 10 wks,28 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anosmia score</measure>
    <time_frame>0, 2 wks, 10 wks, 28 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scratch n Sniff cards</measure>
    <time_frame>0, 2 wks, 10 wks, 28 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OUCC</measure>
    <time_frame>0, 2 wks, 10 wks, 28 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 mcg Synacthen test</measure>
    <time_frame>0, 2 wks, 10 wks, 28 wks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Nasal Polyps</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets for 2 weeks followed by fluticasone nasal drops 800mcg/d for 2 months followed by fluticasone nasal spray 400 mcg/d for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg Prednisolone OD for 2 weeks followed by Fluticasone nasal drops 800 mcg/d for 2 months, followed by fluticasone nasal spray 400mcg/day for 4 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>tablets 25 mg/day</description>
    <arm_group_label>Prednisolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablets once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fluticasone nasal drops</intervention_name>
    <description>fluticasone nasal drops 800mcg/d</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Prednisolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fluticasone nasal spray</intervention_name>
    <description>fluticasone nasal spray 400 mcg/d</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Prednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female

          -  18-75 years of age

          -  bilateral nasal polyposis Grade 2 and above

          -  with or without asthma

          -  with or without atopy or aspirin sensitivity

          -  written informed consent

        Exclusion Criteria:

          -  unilateral nasal polyposis

          -  polypoid lesion suspicious of inverted papilloma, malignancy, Wegeners granulomatosis,
             sarcoidosis

          -  known or suspected hypersensitivity to fluticasone propionate or any other
             constituents of the Investigational Medicinal product (IMP).

          -  Any clinically significant medical condition or abnormality, which, in the opinion of
             the investigator, might compromise the safety of the subject or which might interfere
             with the study.

          -  significant (â‰¥50%)septal deviation

          -  inability to comply with the requirements of the protocol

          -  females who are pregnant, lactating or planning to become pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sriram Vaidyanathan, MRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian J Lipworth, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ninewells Hospital and Medical School</name>
      <address>
        <city>Dundee</city>
        <state>Angus</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2008</study_first_submitted>
  <study_first_submitted_qc>November 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2008</study_first_posted>
  <last_update_submitted>November 10, 2008</last_update_submitted>
  <last_update_submitted_qc>November 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Sriram Vaidyanathan</name_title>
    <organization>University of Dundee</organization>
  </responsible_party>
  <keyword>chronic rhinosinusitis</keyword>
  <keyword>nasal polyps</keyword>
  <keyword>oral steroid</keyword>
  <keyword>intranasal steroid</keyword>
  <keyword>medical polypectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

